Results 41 to 50 of about 3,785 (146)

Limited Sampling Strategies to Predict Ganciclovir Exposure after Valganciclovir Administration and to Reduce Monitoring Constraints in Renal Transplant Children

Antimicrobial Agents and Chemotherapy, 2023
Valganciclovir, the ganciclovir prodrug, is an antiviral agent used to prevent cytomegalovirus infection in renal transplant children. Therapeutic drug monitoring is still necessary to ensure optimal therapeutic area under the concentration-time curve ...
A. Facchin, N. Benyoub, V. Elie, S. Magréault, É. Jacqz-Aigrain   +4 more
semanticscholar   +1 more source

Oral Valganciclovir Therapy in Infants Aged ≤2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan

Journal of Clinical Medicine, 2022
Our aims were to determine the clinical impact of oral valganciclovir (VGCV) in infants aged ≤2 months with congenital cytomegalovirus (CMV) disease and evaluate the efficacy of VGCV when initiated beyond the neonatal period. The multicenter, single-arm,
I. Morioka, Y. Kakei, T. Omori, K. Nozu, K. Fujioka, Naoto Takahashi, T. Yoshikawa, H. Moriuchi, Yoshinori Ito, Akira Oka   +9 more
semanticscholar   +1 more source

Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia

Transplantology, 2021
Cytomegalovirus (CMV) prophylaxis with valganciclovir is the standard of practice in most transplant centers, but treatment-related leukopenia can limit valganciclovir’s use.
Arindam Singha, Pamela K. Burcham, April Logan, Zeinab El Boghdadly, Molly M. Howsare, David R. Nunley, Mark E. Lustberg, Brian C. Keller   +7 more
doaj   +1 more source

Valganciclovir in Infants with Hearing Loss and Clinically Inapparent Congenital Cytomegalovirus Infection: A Nonrandomized Controlled Trial.

Jornal de Pediatria
OBJECTIVE To assess the efficacy of valganciclovir in infants with hearing loss and clinically inapparent congenital cytomegalovirus infection (cCMV), as there is no consensus on treatment of this group.
Pui Khi Chung, F. Schornagel, W. Soede, E. V. van Zwet, A. Kroes, A. Oudesluys-Murphy, A. C. Vossen   +6 more
semanticscholar   +1 more source

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis

Microbiology spectrum, 2022
This study examined the pharmacokinetics and viral genomic data from a prospective cohort of kidney transplant recipients undergoing valganciclovir prophylaxis for cytomegalovirus (CMV) prevention.
Diana D. Y. Wong, Wendy J M van Zuylen, Talia Novos, S. Stocker, S. Reuter, Jane-Phan Au, C. Foster, R. Day, A. Horvath, Z. Endre, W. Rawlinson   +10 more
semanticscholar   +1 more source

Oral Valganciclovir Initiated beyond One Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial.

Jornal de Pediatria
OBJECTIVE To determine if valganciclovir initiated after 1 month of age improves congenital cytomegalovirus (cCMV(-associated sensorineural hearing loss (SNHL). STUDY DESIGN We conducted a randomized, double-blind, placebo-controlled phase 2 trial of 6
D. Kimberlin, Inmaculada Aban, K. Peri, Javier K Nishikawa, J. Bernatoniene, M. Emonts, Nigel Klein, A. Bamford, Roberta L DeBias, Saul N. Faust, Christine E. Jones, P. McMaster, M. Caserta, Amina Ahmed, Mike Sharland, Gail J Demmler-Harrison, S. Hackett, Pablo J. Sánchez, F. Shackley, D. Kelly, P. Dennehy, Gregory A. Storch, Richard J. Whitley, P. Griffiths   +23 more
semanticscholar   +1 more source

Valganciclovir—Ganciclovir Use and Systematic Therapeutic Drug Monitoring. An Invitation to Antiviral Stewardship

Antibiotics, 2021
Valganciclovir (VGCV) and ganciclovir (GCV) doses must be adjusted according to indication, renal function and weight. No specific therapeutic exposure values have been established.
A. Galar, M. Valerio, P. Catalán, X. García-González, A. Burillo, A. Fernández‐Cruz, E. Zatarain, I. Sousa-Casasnovas, F. Anaya, M. L. Rodríguez-Ferrero, P. Muñoz, E. Bouza   +11 more
semanticscholar   +1 more source

Incidence of valganciclovir‐related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease

Transplant Infectious Disease
Valganciclovir (VGCV) prophylaxis is associated with an increased risk of hematologic side effects. We analyzed the impact of VGCV prophylaxis on leukopenia and neutropenia rates and explored risk factors for its occurrence.
S. Belga, Cristina Hernández, D. Kabbani, Carlos Cervera   +3 more
semanticscholar   +1 more source

Experience of Using the Antiviral Therapy of Generalized Congenital Cytomegalovirus Infection

Детские инфекции (Москва), 2016
The article presents the results of observation and treatment with ganciclovir and oral valganciclovir form of a premature infant with congenital generalized symptomatic cytomegalovirus infection (CMVI) involving pathology of CNS, cholangitis ...
G. V. Petrova, V. I. Shakhgildyan, E. A. Chistozvonova, T. A. Pugacheva, N. V. Turkot, M. V. Egorova, O. U. Sautenko, I. B. Astasheva, O. V. Romanova, N. V. Kostycheva, T. A. Grigorieva, M. G. Kulagina   +11 more
doaj   +1 more source

Sensitive determination of valganciclovir via Ni–Co multilayer nanowire-modified carbon paste electrode

RSC Advances
This study presents the development of an electrochemical sensor based on a carbon paste electrode modified with nickel–cobalt multilayer nanowires (Co–Ni(MLNW)/CPE) for the detection of valganciclovir, an antiviral drug.
Maedeh Malekzadeh, A. Rafati, Ahmad Bagheri   +2 more
semanticscholar   +1 more source